Hypertonic saline reduces lipopolysaccharide-induced mouse brain edema through inhibiting aquaporin 4 expression
© Cao et al.; licensee BioMed Central Ltd. 2012
Received: 26 March 2012
Accepted: 4 October 2012
Published: 4 October 2012
Three percent sodium chloride (NaCl) treatment has been shown to reduce brain edema and inhibited brain aquaporin 4 (AQP4) expression in bacterial meningitis induced by Escherichia coli. Lipopolysaccharide (LPS) is the main pathogenic component of E. coli. We aimed to explore the effect of 3% NaCl in mouse brain edema induced by LPS, as well as to elucidate the potential mechanisms of action.
Three percent NaCl was used to treat cerebral edema induced by LPS in mice in vivo. Brain water content, IL-1β, TNFα, immunoglobulin G (IgG), AQP4 mRNA and protein were measured in brain tissues. IL-1β, 3% NaCl and calphostin C (a specific inhibitor of protein kinase C) were used to treat the primary astrocytes in vitro. AQP4 mRNA and protein were measured in astrocytes. Differences in various groups were determined by one-way analysis of variance.
Three percent NaCl attenuated the increase of brain water content, IL-1β, TNFα, IgG, AQP4 mRNA and protein in brain tissues induced by LPS. Three percent NaCl inhibited the increase of AQP4 mRNA and protein in astrocytes induced by IL-1β in vitro. Calphostin C blocked the decrease of AQP4 mRNA and protein in astrocytes induced by 3% NaCl in vitro.
Osmotherapy with 3% NaCl ameliorated LPS-induced cerebral edema in vivo. In addition to its osmotic force, 3% NaCl exerted anti-edema effects possibly through down-regulating the expression of proinflammatory cytokines (IL-1β and TNFα) and inhibiting the expression of AQP4 induced by proinflammatory cytokines. Three percent NaCl attenuated the expression of AQP4 through activation of protein kinase C in astrocytes.
Keywordshypertonic saline lipopolysaccharide brain edema aquaporin 4 protein kinase C interleukin-1 beta
Hypertonic saline (HS) has been widely used in the treatment of patients with brain edema resulting from cerebral infarction, hemorrhage or traumatic brain injury [1–8], and the therapeutic efficiency of HS has also been proved by animal studies [9–13]. Previous reports suggested that HS was more effective in treating brain edema resulting from cerebral hemorrhage, ischemic or traumatic brain injury, as compared with equiosmolar doses of mannitol, in animal studies [9, 12] and clinical trials [14–17]. Our previous study confirmed that adjunctive 3% (1,026 mOsm/L) NaCl treatment reduced brain edema and attenuated brain damage with a superior effect over 20% mannitol in a rabbit bacterial meningitis model . These studies indicated that HS has superior action to mannitol in the treatment of brain edema, in addition to its osmotic effect.
However, little was known of the action of HS besides its osmotic effect in the treatment of brain edema. HS has been suggested to be superior to mannitol as a hyperosmolar agent because it augments intravascular volume and cardiovascular performance in addition to causing 'dehydration' of the brain. In both animal and human studies, HS has been shown to produce a prolonged increase in intravascular volume and plasma volume expansion. In doing so, mean arterial pressure is increased and cerebra1 perfusion pressure is improved [9, 18]. HS has also been shown to have anti-inflammatory effects, which, in turn, modulate blood-brain barrier (BBB) permeability [7, 19]. Zeynalov et al. reported that HS attenuates BBB disruption depending on the presence of perivascular aquaporin 4 (AQP4) in post-ischemic cerebral edema. AQP4 is the primary water channel found in the brain, which is expressed in astrocyte foot processes, in ependymal cells, and in subependymal astrocytes [21, 22]. The expression of AQP4 is up-regulated in wild type mice and AQP4 null mice have significantly less brain edema in water intoxication cerebral edema, ischemic stroke and pneumococcal meningitis [23, 24]. This suggests that AQP4 plays an important role in brain edema formation. Zeng et al. reported that 10% NaCl can down-regulate expression of AQP4 in perivascular astrocytes in a rat cerebral ischemic edema model . Recently, we reported that 3% NaCl inhibited the up-regulation of brain AQP4 protein expression in bacterial meningitis induced by Escherichia coli in rabbits . However, the mechanism of HS down-regulation of AQP4 expression still remains unclear. Lipopolysaccharide (LPS) is the main pathogenic component of E.coli Gram-negative bacterium. Administration of LPS to animals causes pathogenesis, mimicking what occurs in patients [26, 27]. LPS can induce cerebral edema formation and up-regulate expression of brain AQP4 in the mouse . Investigating the effect of HS on up-regulation of brain AQP4 during LPS-induced mice brain edema would provide clues to reveal the mechanism of HS down-regulation of brain AQP4 in bacterial meningitis.
Protein kinase C (PKC) is a family of serine- and threonine-specific protein kinases and plays an important role in the regulation of AQP4 expression. Activation of PKC with phorbol 12, 13-dibutyrate reduces the AQP4 water permeability of LLC-PK1 cells transfected with AQP4 cDNA constructs . Treatment of rat astrocytes with phorbol ester 12-O-tetradecanoylphorbol 13-acetate, a PKC activator, causes a decrease in AQP4 mRNA and protein, which can be inhibited by PKC inhibitors . AQP4 up-regulation and brain edema formation were attenuated by phorbol 12-myristate 13-acetate, a PKC activator, in a rat cerebral ischemia model [31–33]. HS increases total PKC activity and induces PKCα, PKCd, and PKCe translocation from the cytosol to the membrane in NIH/3T3 cells . We hypothesized that activation of PKC would contribute to down-regulation of AQP4 expression induced by HS.
Thus, in the present study we investigated the effects of 3% NaCl on brain AQP4 expression in cerebral edema induced by LPS. Additionally, we also investigated the role of PKC in mediating the down-regulation of AQP4 expression induced by HS in primary astrocytes.
Materials and methods
Animals and experimental groups
Isolation and treatment of astrocytes
Astrocytes were isolated from newborn Sprague-Dawley rats, using a method described by Nicholson and Renton . Briefly, after removal of the meninges, brains of newborn Sprague-Dawley rats were disaggregated using nylon sieves (120 mm pore size) and seeded in 50-ml tissue culture flasks in (D)MEM containing 20% heat-inactivated FCS. Growth medium was replaced on the third and sixth day with (D)MEM containing 20% FCS. On day 10, subcultures were made by treating the cells with 0.25% trypsin:0.25% ethylenediaminetetraacetic acid (EDTA) and, after washing, 1 × 106 cells/ml plated in a 50-ml tissue culture flask in (D)MEM with 10% FCS. After a two-week incubation, cultures were approximately 90% to 95% confluent and contained predominantly astrocytes, with a minor contribution of microglia and oligodendrocytes (3% and 2%, respectively) as determined by immunocytochemistry using antibodies directed against the astrocyte marker glial fibrillary acid protein . Then, the cells were randomly divided into control group, IL-1β group, IL-1β + HS group, IL-1β + calphostinC group and IL-1β + calphostinC + HS group. IL-1β group cells were incubated for six hours with fresh serum-free (D)MEM, containing IL-1β (5 ng/mL) (Recombinant Rat Interleukin-1 beta, ProSpec-Tany TechnoGene Ltd, Rehovot, Israel). IL-1β + HS group cells were incubated with fresh serum-free (D)MEM (containing IL-1β 5 ng/mL) for 3 hours, 3% NaCl for 15 minutes and fresh serum-free (D)MEM (containing IL-1β 5 ng/mL) for 3 hours. Treatment of IL-1β + calphostin C + HS group cells was the same as IL-1β + HS group cells, except for pretreatment with calphostin C (5 uM; Sigma) for 30 minutes before 3% NaCl. The control group received 0.9% NaCl instead of 3% NaCl and the fresh serum-free (D)MEM.
Brain water content
The brains were removed from the mice at the end of the experiment, weighed immediately and then kept at 106°C for 72 hours. The brains were weighed during this process at 48 hours and then again at 72 hours to make sure they had reached a consistent weight. Brain edema was estimated by comparing wet to dry weight ratios. Tissues were weighed with a scale to within 0.001 mg. The percentage of brain water in the tissue was calculated as (wet weight - dry weight) ×100/wet weight.
Detection of IL-1β, TNFα protein and IgG by ELISA
Briefly, animals were sacrificed at the end of the experiment and the whole brain from each animal was collected and weighed immediately. The brain tissue was homogenized with a glass homogenizer with the ratio of 100 mg tissue:1 ml ice-cold PBS (pH 7.4) and centrifuged at 12,000 g for 20 minutes at 4°C. IL-1β, TNFα protein and IgG in the brain tissues were detected by ELISA, following the manufacturer's instructions(Mouse IL-1β ELISA Kit/Mouse TNFα ELISA Kit/Mouse IgG ELISA Kit)(R&D Systems Inc., Minneapolis, MN USA). Data were acquired using a 96-well plate reader. The contents are expressed as pg cytokines/g tissue or ng IgG/g tissue.
Brain edema could be due to both vasogenic and cytotoxic changes. The destruction of the BBB leads to vasogenic cerebral edema. To gain insight into this possibility, the BBB integrity was assessed by analyzing plasma IgG extravasation via ELISA. IgG is a plasma protein which exists mainly in the vascular. Abnormal permeability to IgG occurs after breakdown of the BBB and an increase of IgG in brain tissues can indicate breakdown of the BBB [37, 38].
Proteins were extracted from brain tissue using a total protein extraction kit (Pulilai Gene Technology Co., Ltd., Beijing, China) according to the manufacturer's protocol. Samples of supernatants containing protein were heated to 100°C for 5 minutes. Protein bands were electroblotted onto polyvinylindene difluoride membranes (Millipore, Boston, Massachusetts, USA). After transfer, the membranes were blocked with 5% nonfat milk in tris-buffered saline for 0.5 hours, and then incubated with the primary antibodies according to the manufacturer's recommendations. The primary antibodies used were as follows: AQP4 (rabbit polyclonal antibody 1:200, Beijing Biosynthesis Biotechnology Co., Ltd, Beijing, China), GAPDH (rabbit polyclonal antibody 1:3,000, Nanjing Genscript Corporation, Nanjing, China). After being washed three times with tris-buffered saline with 0.1% Tween-20, the membranes were incubated with the horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5,000)(Nanjing Genscript Corporation) for 1 hour. Bands were visualized using the ECL kit per the manufacturer's manual(LumiGOLD ECL Western Blotting Detection Kit, SignaGen Laboratories, Gaithersburg, MD USA). The signal intensity of AQP4 levels in each group (n = 4) was measured.
Total RNA was extracted from brain tissues or cells with trizol reagent (ShineGene, Shanghai, China) and contaminating genomic DNA was removed with RNasefree DNase I (ShineGene). RT-PCR was performed using a first-strand cDNA synthesis kit (ShineGene) following the manufacturer's instructions.
Quantitative RT-PCR was carried out on an FTC2000 real-time PCR system using a FastStart DNA Master plus SYBR Green I kit (ShineGene) following the manufacturer's instructions. The primers used were: AQP4(213 bp), Forward: GCTTTCTGGAAGGCAGTCTCA, Reverse: GGCTACAGTCACAGCGGGA; IL-1(196 bp), Forward: GCTTCAGGCAGGCAGTATCA, Reverse: TGCAGTTGTCTAATGGG AACG; TNFα(156 bp), Forward: TACTGAA CTTCGGGGTGATCG, Reverse: CCACTTGGTGGTTTGCTACG; β-actin(263 bp), Forward: GAGACCTTCAACACCCCAGC, Reverse: ATGTCACGCACGATTTC CC(Mouse); AQP4(138 bp), Forward: CGC CAAGTCCGTCTTCTACA, Reverse: GCCAGCAGTGAGGTTTCCAT, β-actin(150 bp), Forward: CCCATCTATGAGGGTTACGC, Reverse: TTTAATGTCACGCACGA TTTC(rat). The first segment of the amplification cycle consisted of a denaturation program at 94°C for 4 minutes. The second segment consisted of denaturation, primer annealing, elongation and a quantification program repeated for 35 cycles. The third segment consisted of a melting curve program. The final segment consisted of a cooling program at 72°C. The expression of target genes was measured in tetramerous, and was normalized to β-actin. Gene expression was quantified using a modification of the 2(-Delta Delta C(T)) method as previously described.
With direct staining, astrocytes were incubated with AQP4-PE (Santa Cruz Biotechnology, Santa Cruz, CA USA) antibody, a monoclonal antibody conjugated to a fluorochrome phycoerythrin. This procedure was quick and direct; it merely involved a half-hour incubation of cells with antibody (at 4°C), followed by several washes to remove weakly or nonspecifically bound antibodies. Cells thus treated were ready for flow analysis (although final fixation with 1% electron microscopic-grade formaldehyde provided a measure of biological safety and long-term stability). The mean fluorescence intensity of cells was measured in tetramerous with a flow cytometer (Beckman Coulter Co., Caguas, PR USA).
All values were presented as mean ± S.E.M. Differences in various groups were determined by one-way analysis of variance. A value of P < 0.05 was considered statistically significant.
Three percent NaCl attenuated brain edema induced by LPS
Three percent NaCl inhibited the increase of IL-1β and TNFα in brain tissues induced by LPS
Three percent NaCl blocked the increase of AQP4 mRNA and protein in brain tissues induced by LPS in vivo
Three percent NaCl blocked the increase of AQP4 mRNA and protein in the primary astrocytes induced by IL-1β through activation of PKC in vitro
LPS is the critical pathogenic component of gram-negative bacteria. Administration of LPS to rats or mice induces up-regulated expression of IL-1β and TNFα in brain tissues, disruption of the BBB and brain edema formation [28, 41–43]. Brain edema has traditionally been classified into three major types: cytotoxic, vasogenic and interstitial . The mechanisms of brain edema induce by LPS are not fully elucidated. The proinflammatory cytokines of IL-1β and TNFα and complement cascade may play an important role in development of brain edema induced by LPS [28, 41, 43]. Hypertonic solutions are a mainstay of osmotherapy for cerebral edema. The accepted view is that the potent anti-edema effect of HS is affected primarily via egress of water from the interstitial and extracellular space into the intravascular compartment through an intact BBB [11, 45, 46]. In addition to this primary action, HS has been shown to exert beneficial non-osmotic cerebral effects. Our previous study confirmed that adjunctive 3% NaCl treatment inhibited the expression of inflammatory factors in a rabbit bacterial meningitis model . Our results confirm that intraperitoneal injection of LPS induced up-regulated expression of IL-1β and TNFα, disruption of the BBB and brain edema. Adjunctive 3% NaCl treatment for 2 hours could effectively reduce brain edema induced by LPS. After treatment with 3% NaCl for 6 hours, IL-1β and TNFα mRNA and protein, and IgG in brain tissues decreased significantly and brain water content did not appear to rebound. We further confirmed that in addition to its osmotic force, 3% NaCl could inhibit expression of IL-1β and TNFa, alleviate disruption of the BBB and reduce cerebral edema induced by LPS.
AQP4 is a water-channel protein predominantly expressed in astrocyte foot processes at the borders between the brain parenchyma and major fluid compartments, and in ependymal cells lining the ventricles in contact with cerebrospinal fluid in the brain [22, 47]. This distribution suggests that AQP4 probably participates in water fluxes into and out of the brain parenchyma. AQP4 is up-regulated in the brain in ischemic brain edema [48, 49]. AQP4 probably plays a critical role in reabsorption of cerebrospinal fluid and regulation of brain edema . AQP4 null mice have lower mortality and are less prone to cytotoxic brain edema, including water intoxication cerebral edema , early focal cerebral ischemia  and bacterial meningitis . Accordingly, overexpression of AQP4 in transgenic mice accelerates progression of cytotoxic brain swelling . Down-regulation of AQP4 could be a way in which HS ameliorates cerebral edema [11, 20, 25]. AQP4 down-regulation slows the rate of water entry into the brain in cytotoxic edema. Our results show that injection of LPS could up-regulate expression of AQP4 mRNA and protein, which is consistent with previous reports [28, 37, 43]. Our results also showed for the first time that 3% NaCl could down-regulate expression of AQP4 mRNA and protein in the brain edema induced by LPS. This may be another non-osmotic mechanism of HS in the treatment of cerebral edema induced by LPS.
The mechanism of HS down-regulation of AQP4 expression in cerebral edema is not yet known. Different authors have observed that HS could down-regulate the expression of AQP4 in cerebral edema induced by stroke , bacterial meningitis  or local cryoinjury . However, they did not study the mechanism of HS down-regulation of AQP4 expression in cerebral edema. Proinflammatory cytokines are released as an important part of LPS induced brain injury. Previous study has shown that IL-1β induces the expression of AQP4 in primary astrocytes . It is also reported that TNFα is a key mediator of brain edema formation, disruption of the BBB and up-regulation of AQP4 expression induced by LPS . These studies suggest that LPS induced up-regulated expression of AQP4 probably through increasing the production of IL-1β or TNFα. Cuschieri et al. reported that HS preconditioning reduces TNFα production induced by LPS in alveolar macrophages . Present results show that 3% NaCl treatment reduced the up-regulation of AQP4 expression and reduced the production of IL-1β and TNFα induced by LPS in vivo. All of the above suggest that 3% NaCl induced down-regulation of AQP4 expression and attenuated disruption of the BBB induced by LPS, probably through limiting the production of proinflammatory cytokines (IL-1β and TNFα) in LPS-induced brain edema.
Astrocytes are the main cell type that swell in cytotoxic brain edema  and the cells are also the main cell type that express AQP4 in the brain . We further investigated the effect of HS on AQP4 expression induced by IL-1β in astrocytes in vitro to explore the mechanism of HS down-regulation of brain AQP4. The results show that IL-1β significantly increased the AQP4 mRNA and membrane protein level in the astrocytes in vitro and that 3% NaCl attenuated the increase of AQP4 mRNA and protein induced by IL-1β. These results indicate that 3% NaCl also directly antagonizes the IL-1β action of inhibiting up-regulated expression of AQP4 in the astrocytes. This may be another mechanism by which 3% NaCl inhibits the up-regulation of AQP4 expression induced by LPS.
PKC serves as a second messenger for G-protein receptors that are coupled to the phosphoinositide pathway, causing either a transient rise in intracellular Ca2+, through inositol-triphosphate or activating PKC through diacylglycerol. Previous studies have shown that activation of PKC decreases the expression of AQP4 in rat astrocytes  and attenuates AQP4 up-regulation and brain edema formation [31–33].
Pretreatment of the cultured rat astrocytes with cycloheximide (an inhibitor of protein synthesis) or actinomycin D (an inhibitor of transcription) does not change the decrease in AQP4 mRNA induced by the phorbol ester 12-O-tetradecanoylphorbol 13-acetate . It is suggested that PKC may be involved in AQP4 regulation on the transcriptional level, rather than affecting de novo protein synthesis or the stability of AQP4 mRNA. Tang et al. reported that thrombin inhibits AQP4 expression through a PKC-dependent pathway in cultured astrocytes . It is reported that 3% NaCl can activate PKC . PKC mu performs a critical function in hypertonicity-induced heat shock protein 70 expression in NIH3T3 cells . These findings suggest that the 3% NaCl not only can activate PKC but also causes changes in gene expression mediated by the PKC in the cell. We used the PKC inhibitor of calphostin C to further identify the role of PKC in HS down-regulation of the expression of AQP4. Our results demonstrated that calphostin C attenuated the decrease of AQP4 expression induced by 3% NaCl in the primary astrocytes. The results indicate that 3% NaCl can attenuate the expression of AQP4 through activation of PKC.
This study shows that osmotherapy with 3% NaCl ameliorated LPS-induced cerebral edema in vivo. In addition to its osmotic force, 3% NaCl exerted anti-edema effects possibly through down-regulating the expression of proinflammatory cytokines (IL-1β and TNFα) and inhibiting the expression of AQP4 induced by proinflammatory cytokines. Three percent NaCl attenuated the expression of AQP4 through activation of PKC in astrocytes. However, the optimal HS dose for reducing AQP4 expression, the pathway of activating PKC by HS and the significance of HS down-regulation of AQP4 in brain edema are to be further explored.
3% NaCl attenuated brain edema induced by LPS.
3% NaCl inhibited the increase of IL-1β and TNFα in brain tissues induced by LPS.
3% NaCl blocked the increase of AQP4 mRNA and protein in brain tissues induced by LPS in vivo.
3% NaCl blocked the increase of AQP4 mRNA and protein in the primary astrocytes induced by IL-1β through activation of PKC in vitro.
brain water content
(Dulbecco's) modified Eagle's medium
enzyme-linked immunosorbent assay
fetal calf serum
protein kinase C
reverse transcriptase-polymerase chain reaction
tumor necrosis factor alpha.
This study was supported by grants from the National Natural Science Foundation of China (No: 81070970), Specialized Research Fund for the Doctoral Program of Higher Education (No: 20090162110016), the Open-End Fund for the Valuable and Precision Instruments of Central South University and Research Fund of Development and Research Fund of Development and Reform Commission of Hunan Province (No:2010).
- Schwarz S, Schwab S, Bertram M, Aschoff A, Hacke W: Effects of hypertonic saline hydroxyethyl starch solution and mannitol in patients with increased intracranial pressure after stroke. Stroke 1998, 29: 1550-1555. 10.1161/01.STR.29.8.1550View ArticlePubMedGoogle Scholar
- Schwarz S, Georgiadis D, Aschoff A, Schwab S: Effects of hypertonic (10%) saline in patients with raised intracranial pressure after stroke. Stroke 2002, 33: 136-140. 10.1161/hs0102.100877View ArticlePubMedGoogle Scholar
- Suarez JI, Qureshi AI, Parekh PD, Razumovsky A, Tamargo RJ, Bhardwaj A, Ulatowski JA: Administration of hypertonic (3%) sodium chloride/acetate in hyponatremic patients with symptomatic vasospasm following subarachnoid hemorrhage. J Neurosurg Anesthesiol 1999, 11: 178-184. 10.1097/00008506-199907000-00004View ArticlePubMedGoogle Scholar
- Hartl R, Ghajar J, Hochleuthner H, Mauritz W: Hypertonic/hyperoncotic saline reliably reduces ICP in severely head-injured patients with intracranial hypertension. Acta Neurochir Suppl 1997, 70: 126-129.PubMedGoogle Scholar
- Shackford SR, Bourguignon PR, Wald SL, Rogers FB, Osler TM, Clark DE: Hypertonic saline resuscitation of patients with head injury: a prospective, randomized clinical trial. J Trauma 1998, 44: 50-58. 10.1097/00005373-199801000-00004View ArticlePubMedGoogle Scholar
- Qureshi AI, Suri MF, Ringer AJ, Guterman LR, Hopkins LN: Regional intraparenchymal pressure differences in experimental intracerebral hemorrhage: effect of hypertonic saline. Crit Care Med 2002, 30: 435-441. 10.1097/00003246-200202000-00028View ArticlePubMedGoogle Scholar
- Ziai WC, Toung TJ, Bhardwaj A: Hypertonic saline: first-line therapy for cerebral edema? J Neurol Sci 2007, 261: 157-166. 10.1016/j.jns.2007.04.048View ArticlePubMedGoogle Scholar
- Peterson B, Khanna S, Fisher B, Marshall L: Prolonged hypernatremia controls elevated intracranial pressure in head-injured pediatric patients. Crit Care Med 2000, 28: 1136-1143. 10.1097/00003246-200004000-00037View ArticlePubMedGoogle Scholar
- Qureshi AI, Wilson DA, Traystman RJ: Treatment of elevated intracranial pressure in experimental intracerebral hemorrhage: comparison between mannitol and hypertonic saline. Neurosurgery 1999, 44: 1055-1063; discussion 1063-1054. 10.1097/00006123-199905000-00064View ArticlePubMedGoogle Scholar
- Heimann A, Takeshima T, Alessandri B, Noppens R, Kempski O: Effects of hypertonic/hyperoncotic treatment after rat cortical vein occlusion. Crit Care Med 2003, 31: 2495-2501. 10.1097/01.CCM.0000084893.44650.CBView ArticlePubMedGoogle Scholar
- Liu S, Li L, Luo Z, Wang M, She H, Yu X, Deng X, Huang F, Shang L, Jian C, Ji G, Yue S: Superior effect of hypertonic saline over mannitol to attenuate cerebral edema in a rabbit bacterial meningitis model. Crit Care Med 2011, 39: 1467-1473. 10.1097/CCM.0b013e3182120d13View ArticlePubMedGoogle Scholar
- Zeng HK, Wang QS, Deng YY, Jiang WQ, Fang M, Chen CB, Jiang X: A comparative study on the efficacy of 10% hypertonic saline and equal volume of 20% mannitol in the treatment of experimentally induced cerebral edema in adult rats. BMC Neurosci 2010, 11: 153. 10.1186/1471-2202-11-153PubMed CentralView ArticlePubMedGoogle Scholar
- da Silva JC, de Lima Fde M, Valenca MM, de Azevedo Filho HR: Hypertonic saline more efficacious than mannitol in lethal intracranial hypertension model. Neurol Res 2010, 32: 139-143. 10.1179/174313209X405119View ArticlePubMedGoogle Scholar
- Vialet R, Albanese J, Thomachot L, Antonini F, Bourgouin A, Alliez B, Martin C: Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol. Crit Care Med 2003, 31: 1683-1687. 10.1097/01.CCM.0000063268.91710.DFView ArticlePubMedGoogle Scholar
- Battison C, Andrews PJ, Graham C, Petty T: Randomized, controlled trial on the effect of a 20% mannitol solution and a 7.5% saline/6% dextran solution on increased intracranial pressure after brain injury. Crit Care Med 2005, 33: 196-202; discussion 257-198. 10.1097/01.CCM.0000150269.65485.A6View ArticlePubMedGoogle Scholar
- Francony G, Fauvage B, Falcon D, Canet C, Dilou H, Lavagne P, Jacquot C, Payen JF: Equimolar doses of mannitol and hypertonic saline in the treatment of increased intracranial pressure. Crit Care Med 2008, 36: 795-800. 10.1097/CCM.0B013E3181643B41View ArticlePubMedGoogle Scholar
- Kamel H, Navi BB, Nakagawa K, Hemphill JC, Ko NU: Hypertonic saline versus mannitol for the treatment of elevated intracranial pressure: a meta-analysis of randomized clinical trials. Crit Care Med 2011, 39: 554-559. 10.1097/CCM.0b013e318206b9beView ArticlePubMedGoogle Scholar
- Knapp JM: Hyperosmolar therapy in the treatment of severe head injury in children: mannitol and hypertonic saline. AACN Clin Issues 2005, 16: 199-211. 10.1097/00044067-200504000-00011View ArticlePubMedGoogle Scholar
- Chen CH, Toung TJ, Sapirstein A, Bhardwaj A: Effect of duration of osmotherapy on blood-brain barrier disruption and regional cerebral edema after experimental stroke. J Cereb Blood Flow Metab 2006, 26: 951-958. 10.1038/sj.jcbfm.9600248View ArticlePubMedGoogle Scholar
- Zeynalov E, Chen CH, Froehner SC, Adams ME, Ottersen OP, Amiry-Moghaddam M, Bhardwaj A: The perivascular pool of aquaporin-4 mediates the effect of osmotherapy in postischemic cerebral edema. Crit Care Med 2008, 36: 2634-2640. 10.1097/CCM.0b013e3181847853PubMed CentralView ArticlePubMedGoogle Scholar
- Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP: Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 1997, 17: 171-180.PubMedGoogle Scholar
- Rash JE, Yasumura T, Hudson CS, Agre P, Nielsen S: Direct immunogold labeling of aquaporin-4 in square arrays of astrocyte and ependymocyte plasma membranes in rat brain and spinal cord. Proc Natl Acad Sci USA 1998, 95: 11981-11986. 10.1073/pnas.95.20.11981PubMed CentralView ArticlePubMedGoogle Scholar
- Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, Bollen AW, Chan P, Verkman AS: Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 2000, 6: 159-163. 10.1038/72256View ArticlePubMedGoogle Scholar
- Papadopoulos MC, Verkman AS: Aquaporin-4 gene disruption in mice reduces brain swelling and mortality in pneumococcal meningitis. J Biol Chem 2005, 280: 13906-13912. 10.1074/jbc.M413627200View ArticlePubMedGoogle Scholar
- Zeng HK, Wang QS, Deng YY, Fang M, Chen CB, Fu YH, Jiang WQ, Jiang X: Hypertonic saline ameliorates cerebral edema through downregulation of aquaporin-4 expression in the astrocytes. Neuroscience 2010, 166: 878-885. 10.1016/j.neuroscience.2009.12.076View ArticlePubMedGoogle Scholar
- Gardenfors A, Nilsson F, Skagerberg G, Ungerstedt U, Nordstrom CH: Cerebral physiological and biochemical changes during vasogenic brain oedema induced by intrathecal injection of bacterial lipopolysaccharides in piglets. Acta Neurochir (Wien) 2002, 144: 601-608; discussion 608-609. 10.1007/s00701-002-0954-1View ArticleGoogle Scholar
- Radzivil GG, Beloborodov VB, Bronikin Iu V: Hemodynamics and rheologic properties of the blood in meningococcemia associated with meningitis and complicated by septic shock and intracranial hypertension. Anesteziol Reanimatol 1990, 2: 28-33.PubMedGoogle Scholar
- Alexander JJ, Jacob A, Cunningham P, Hensley L, Quigg RJ: TNF is a key mediator of septic encephalopathy acting through its receptor, TNF receptor-1. Neurochem Int 2008, 52: 447-456. 10.1016/j.neuint.2007.08.006PubMed CentralView ArticlePubMedGoogle Scholar
- Zelenina M, Zelenin S, Bondar AA, Brismar H, Aperia A: Water permeability of aquaporin-4 is decreased by protein kinase C and dopamine. Am J Physiol Renal Physiol 2002, 283: F309-318.View ArticlePubMedGoogle Scholar
- Yamamoto N, Sobue K, Miyachi T, Inagaki M, Miura Y, Katsuya H, Asai K: Differential regulation of aquaporin expression in astrocytes by protein kinase C. Brain Res Mol Brain Res 2001, 95: 110-116.View ArticlePubMedGoogle Scholar
- Kleindienst A, Fazzina G, Amorini AM, Dunbar JG, Glisson R, Marmarou A: Modulation of AQP4 expression by the protein kinase C activator, phorbol myristate acetate, decreases ischemia-induced brain edema. Acta Neurochir Suppl 2006, 96: 393-397. 10.1007/3-211-30714-1_81View ArticlePubMedGoogle Scholar
- Okuno K, Taya K, Marmarou CR, Ozisik P, Fazzina G, Kleindienst A, Gulsen S, Marmarou A: The modulation of aquaporin-4 by using PKC-activator (phorbol myristate acetate) and V1a receptor antagonist (SR49059) following middle cerebral artery occlusion/reperfusion in the rat. Acta Neurochir Suppl 2008. AQP4, aquaporin 4; HS, hypertonic saline; LPS, lipopolysaccharide; PCR, polymerase chain reactionGoogle Scholar
- Fazzina G, Amorini AM, Marmarou CR, Fukui S, Okuno K, Dunbar JG, Glisson R, Marmarou A, Kleindienst A: The protein kinase C activator phorbol myristate acetate decreases brain edema by aquaporin 4 downregulation after middle cerebral artery occlusion in the rat. J Neurotrauma 2010, 27: 453-461. 10.1089/neu.2008.0782PubMed CentralView ArticlePubMedGoogle Scholar
- Zhuang S, Hirai SI, Ohno S: Hyperosmolality induces activation of cPKC and nPKC, a requirement for ERK1/2 activation in NIH/3T3 cells. Am J Physiol Cell Physiol 2000, 278: C102-109.PubMedGoogle Scholar
- Nicholson TE, Renton KW: Modulation of cytochrome P450 by inflammation in astrocytes. Brain Res 1999, 827: 12-18. 10.1016/S0006-8993(99)01261-5View ArticlePubMedGoogle Scholar
- Hertz L: Calcium accumulation and calcium effects in astrocytes in primary cultures. Acta Physiol Scand Suppl 1989, 582: 33.PubMedGoogle Scholar
- Tomas-Camardiel M, Venero JL, Herrera AJ, De Pablos RM, Pintor-Toro JA, Machado A, Cano J: Blood-brain barrier disruption highly induces aquaporin-4 mRNA and protein in perivascular and parenchymal astrocytes: protective effect by estradiol treatment in ovariectomized animals. J Neurosci Res 2005, 80: 235-246. 10.1002/jnr.20443View ArticlePubMedGoogle Scholar
- Butt OI, Buehler PW, D'Agnillo F: Blood-brain barrier disruption and oxidative stress in guinea pig after systemic exposure to modified cell-free hemoglobin. Am J Pathol 2011, 178: 1316-1328. 10.1016/j.ajpath.2010.12.006PubMed CentralView ArticlePubMedGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25: 402-408. 10.1006/meth.2001.1262View ArticlePubMedGoogle Scholar
- Ito H, Yamamoto N, Arima H, Hirate H, Morishima T, Umenishi F, Tada T, Asai K, Katsuya H, Sobue K: Interleukin-1beta induces the expression of aquaporin-4 through a nuclear factor-kappaB pathway in rat astrocytes. J Neurochem 2006, 99: 107-118. 10.1111/j.1471-4159.2006.04036.xView ArticlePubMedGoogle Scholar
- Cai Z, Pang Y, Lin S, Rhodes PG: Differential roles of tumor necrosis factor-alpha and interleukin-1 beta in lipopolysaccharide-induced brain injury in the neonatal rat. Brain Res 2003, 975: 37-47. 10.1016/S0006-8993(03)02545-9View ArticlePubMedGoogle Scholar
- Pang Y, Cai Z, Rhodes PG: Disturbance of oligodendrocyte development, hypomyelination and white matter injury in the neonatal rat brain after intracerebral injection of lipopolysaccharide. Brain Res Dev Brain Res 2003, 140: 205-214.View ArticlePubMedGoogle Scholar
- Jacob A, Hensley LK, Safratowich BD, Quigg RJ, Alexander JJ: The role of the complement cascade in endotoxin-induced septic encephalopathy. Lab Invest 2007, 87: 1186-1194. 10.1038/labinvest.3700686View ArticlePubMedGoogle Scholar
- Harukuni I, Kirsch JR, Bhardwaj A: Cerebral resuscitation: role of osmotherapy. J Anesth 2002, 16: 229-237. 10.1007/s005400200030View ArticlePubMedGoogle Scholar
- Forsyth LL, Liu-DeRyke X, Parker D Jr, Rhoney DH: Role of hypertonic saline for the management of intracranial hypertension after stroke and traumatic brain injury. Pharmacotherapy 2008, 28: 469-484. 10.1592/phco.28.4.469View ArticlePubMedGoogle Scholar
- White H, Cook D, Venkatesh B: The role of hypertonic saline in neurotrauma. Eur J Anaesthesiol Suppl 2008, 42: 104-109.View ArticlePubMedGoogle Scholar
- Frigeri A, Gropper MA, Turck CW, Verkman AS: Immunolocalization of the mercurial-insensitive water channel and glycerol intrinsic protein in epithelial cell plasma membranes. Proc Natl Acad Sci USA 1995, 92: 4328-4331. 10.1073/pnas.92.10.4328PubMed CentralView ArticlePubMedGoogle Scholar
- Ribeiro Mde C, Hirt L, Bogousslavsky J, Regli L, Badaut J: Time course of aquaporin expression after transient focal cerebral ischemia in mice. J Neurosci Res 2006, 83: 1231-1240. 10.1002/jnr.20819View ArticlePubMedGoogle Scholar
- Yang M, Gao F, Liu H, Yu WH, Sun SQ: Temporal changes in expression of aquaporin-3, -4, -5 and -8 in rat brains after permanent focal cerebral ischemia. Brain Res 2009, 1290: 121-132.View ArticlePubMedGoogle Scholar
- King LS, Agre P: Pathophysiology of the aquaporin water channels. Annu Rev Physiol 1996, 58: 619-648. 10.1146/annurev.ph.58.030196.003155View ArticlePubMedGoogle Scholar
- Yang B, Zador Z, Verkman AS: Glial cell aquaporin-4 overexpression in transgenic mice accelerates cytotoxic brain swelling. J Biol Chem 2008, 283: 15280-15286. 10.1074/jbc.M801425200PubMed CentralView ArticlePubMedGoogle Scholar
- Jiang W, Cao WJ, Zhang YK, Wei XY, Kuang F: Bolus injection of hypertonic solutions for cerebral edema in rats: challenge of homeostasis of healthy brain. Neurosci Lett 2012, 509: 44-49. 10.1016/j.neulet.2011.12.045View ArticlePubMedGoogle Scholar
- Cuschieri J, Gourlay D, Garcia I, Jelacic S, Maier RV: Hypertonic preconditioning inhibits macrophage responsiveness to endotoxin. J Immunol 2002, 168: 1389-1396.View ArticlePubMedGoogle Scholar
- Kimelberg HK: Current concepts of brain edema. Review of laboratory investigations. J Neurosurg 1995, 83: 1051-1059. 10.3171/jns.19220.127.116.111View ArticlePubMedGoogle Scholar
- Nakahama K, Nagano M, Fujioka A, Shinoda K, Sasaki H: Effect of TPA on aquaporin 4 mRNA expression in cultured rat astrocytes. Glia 1999, 25: 240-246. 10.1002/(SICI)1098-1136(19990201)25:3<240::AID-GLIA4>3.0.CO;2-CView ArticlePubMedGoogle Scholar
- Tang Y, Cai D, Chen Y: Thrombin inhibits aquaporin 4 expression through protein kinase C-dependent pathway in cultured astrocytes. J Mol Neurosci 2007, 31: 83-93. 10.1007/BF02686120View ArticlePubMedGoogle Scholar
- Lim YS, Lee JS, Huang TQ, Seo JS: Protein kinase Cmu plays an essential role in hypertonicity-induced heat shock protein 70 expression. Exp Mol Med 2008, 40: 596-606. 10.3858/emm.2008.40.6.596PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.